Latest Breaking News On - இவன் செயுங் - Page 2 : comparemela.com
At hearing for Hong Kong national security case, judges hear defendant made stupid mistake
asiaone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiaone.com Daily Mail and Mail on Sunday newspapers.
Lawyer for HK protester seeks shorter prison term
taipeitimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taipeitimes.com Daily Mail and Mail on Sunday newspapers.
Eisai Alzheimer s Disease Pipeline Research, Including New Lecanemab (BAN2401) Data, to be Presented at 2021 Alzheimer s Association International Conference (AAIC)
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas
Bloomberg 7 hrs ago © Bloomberg Biogen Partner Pushing On With Second Drug Despite Controversy
(Bloomberg) Fresh off the historic but controversial approval of its Alzheimer’s drug Aduhelm with Biogen Inc. in the U.S., Japanese pharmaceutical company Eisai Co. says it’s pushing ahead with its second therapy to combat the disease, which has shown fewer side effects and could come in a more convenient form for patients.
The Tokyo-based company’s plans for the second drug come amid renewed scrutiny around the U.S. Food and Drug Administration’s June approval of Aduhelm, which caused resignations among a panel of independent experts who said the therapy was ineffective, and has garnered a call for a federal probe in the U.S.
The Tokyo-based company’s plans for the second drug come amid renewed scrutiny around the U.S. Food and Drug Administration’s June approval of Aduhelm, which caused resignations among a panel of independent experts who said the therapy was ineffective, and has garnered a call for a federal probe in the U.S.
Eisai’s second compound in development to treat Alzheimer’s has the potential for fewer side effects like brain swelling and bleeding and could come in an injection enabling at-home administration, rather than intravenous infusions in hospitals, Ivan Cheung, the Woodcliff Lake, New Jersey-based global president of Eisai’s neurology business, told Bloomberg News in an interview last week. The second drug, known as lecanemab or BAN2401, works similarly to Aduhelm by reducing amyloid plaques from the brains of Alzheimer’s patients.